{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:39:29Z","timestamp":1773286769453,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Nichirei Bioscience"},{"name":"Nichirei Biosciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The Biocartis Idylla<jats:sup>\u2122<\/jats:sup> platform is a fully automated, real-time PCR-based diagnostic system. The Idylla<jats:sup>\u2122<\/jats:sup><jats:italic>KRAS<\/jats:italic> and <jats:italic>NRAS<\/jats:italic>-<jats:italic>BRAF<\/jats:italic> Mutation Tests have been developed for the qualitative detection of mutations in <jats:italic>KRAS<\/jats:italic>, <jats:italic>NRAS<\/jats:italic> and <jats:italic>BRAF<\/jats:italic> genes, facilitating the genomic profiling of patients with colorectal cancer. The aim of the present study was to evaluate clinical performances of these tests in Japan.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The <jats:italic>RAS<\/jats:italic> and <jats:italic>BRAF<\/jats:italic> mutation statuses of 253 formalin-fixed paraffin-embedded (FFPE) colorectal cancer tissues were analyzed using the Investigational Use Only Idylla<jats:sup>\u2122<\/jats:sup><jats:italic>KRAS<\/jats:italic> Mutation Test and the Idylla<jats:sup>\u2122<\/jats:sup><jats:italic>NRAS<\/jats:italic>-<jats:italic>BRAF<\/jats:italic> Mutation Test and an in vitro diagnostics (IVD) kit (MEBGEN RASKET<jats:sup>\u2122<\/jats:sup>-B kit).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The success rate for obtaining a valid mutational data without retest of the Idylla tests was 97.6% (247\/253): 111 <jats:italic>KRAS<\/jats:italic> mutations (43.8%), 9 <jats:italic>NRAS<\/jats:italic> mutations (3.6%), and 36 <jats:italic>BRAF<\/jats:italic> V600E mutations (14.2%) were detected using the Idylla tests. Compared with the MEBGEN RASKET-B results, the positive concordance rate was 97.4%, the negative concordance rate was 95.7%, and the overall concordance rate was 95.3% (<jats:italic>\u03ba<\/jats:italic>\u2009=\u20090.919, 95% CI 0.871\u20130.967). The average turnaround time to Idylla<jats:sup>\u2122<\/jats:sup><jats:italic>KRAS<\/jats:italic> and <jats:italic>NRAS<\/jats:italic>-<jats:italic>BRAF<\/jats:italic> Mutation Test was 5.6 working days (range: 3\u201311\u00a0days).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This result demonstrates a high concordance between the Idylla<jats:sup>\u2122<\/jats:sup><jats:italic>KRAS<\/jats:italic> and <jats:italic>NRAS-BRAF<\/jats:italic> Mutation Tests and an existing IVD kit. In this manner, the Idylla<jats:sup>\u2122<\/jats:sup> mutation tests were validated for the detection of clinically significant <jats:italic>KRAS, NRAS, and BRAF<\/jats:italic> mutations in FFPE samples from colorectal cancer\u00a0patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10147-022-02167-z","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T17:04:05Z","timestamp":1650992645000},"page":"1180-1187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Performance of Idylla\u2122 RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer"],"prefix":"10.1007","volume":"27","author":[{"given":"Yusuke","family":"Makutani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Chikugo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Satou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco A.","family":"de Velasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8275-0846","authenticated-orcid":false,"given":"Kazuto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichiro","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,26]]},"reference":[{"issue":"2","key":"2167_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics. CA Cancer J Clin 65(2):87\u2013108. https:\/\/doi.org\/10.3322\/caac.21262","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"2167_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4251\/wjgo.v5.i5.97","volume":"5","author":"K Zenonos","year":"2013","unstructured":"Zenonos K, Kyprianou K (2013) RAS signaling pathways, mutations and their role in colorectal cancer. World J Gastrointest Oncol 5(5):97\u2013101. https:\/\/doi.org\/10.4251\/wjgo.v5.i5.97","journal-title":"World J Gastrointest Oncol"},{"issue":"10","key":"2167_CR3","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.ejca.2015.04.007","volume":"51","author":"C Bokemeyer","year":"2015","unstructured":"Bokemeyer C, Kohne CH, Ciardiello F et al (2015) FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer 51(10):1243\u20131252. https:\/\/doi.org\/10.1016\/j.ejca.2015.04.007","journal-title":"Eur J Cancer"},{"issue":"7","key":"2167_CR4","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/annonc\/mdu141","volume":"25","author":"JY Douillard","year":"2014","unstructured":"Douillard JY, Siena S, Cassidy J et al (2014) Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 25(7):1346\u20131355. https:\/\/doi.org\/10.1093\/annonc\/mdu141","journal-title":"Ann Oncol"},{"issue":"5","key":"2167_CR5","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ejca.2015.01.054","volume":"51","author":"F Pietrantonio","year":"2015","unstructured":"Pietrantonio F, Petrelli F, Coinu A et al (2015) Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 51(5):587\u2013594. https:\/\/doi.org\/10.1016\/j.ejca.2015.01.054","journal-title":"Eur J Cancer"},{"issue":"5","key":"2167_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121891","volume":"10","author":"K Sakai","year":"2015","unstructured":"Sakai K, Tsurutani J, Yamanaka T et al (2015) Extended RAS and BRAF mutation analysis using next-generation sequencing. PLoS ONE 10(5):e0121891. https:\/\/doi.org\/10.1371\/journal.pone.0121891","journal-title":"PLoS ONE"},{"issue":"4","key":"2167_CR7","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1007\/s12253-020-00818-y","volume":"26","author":"S Rossat","year":"2020","unstructured":"Rossat S, Perrier H, Lefevre M et al (2020) Drastic reduction of turnaround time after implementation of a fully automated assay for RAS-BRAF mutations in colorectal cancer: a pilot prospective study in real-life conditions. Pathol Oncol Res 26(4):2469\u20132473. https:\/\/doi.org\/10.1007\/s12253-020-00818-y","journal-title":"Pathol Oncol Res"},{"issue":"5","key":"2167_CR8","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1136\/jclinpath-2015-203345","volume":"69","author":"R Colling","year":"2016","unstructured":"Colling R, Wang LM, Soilleux E (2016) Automated PCR detection of BRAF mutations in colorectal adenocarcinoma: a diagnostic test accuracy study. J Clin Pathol 69(5):398\u2013402. https:\/\/doi.org\/10.1136\/jclinpath-2015-203345","journal-title":"J Clin Pathol"},{"key":"2167_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2016-203696","author":"D de Biase","year":"2016","unstructured":"de Biase D, de Luca C, Gragnano G et al (2016) Fully automated PCR detection of KRAS mutations on pancreatic endoscopic ultrasound fine-needle aspirates. J Clin Pathol. https:\/\/doi.org\/10.1136\/jclinpath-2016-203696","journal-title":"J Clin Pathol"},{"issue":"4","key":"2167_CR10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/jclinpath-2016-203989","volume":"70","author":"C De Luca","year":"2017","unstructured":"De Luca C, Gragnano G, Pisapia P et al (2017) EGFR mutation detection on lung cancer cytological specimens by the novel fully automated PCR-based Idylla EGFR Mutation Assay. J Clin Pathol 70(4):295\u2013300. https:\/\/doi.org\/10.1136\/jclinpath-2016-203989","journal-title":"J Clin Pathol"},{"issue":"29","key":"2167_CR11","doi-asserted-by":"publisher","first-page":"26886","DOI":"10.18632\/oncotarget.4723","volume":"6","author":"F Janku","year":"2015","unstructured":"Janku F, Claes B, Huang HJ et al (2015) BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget 6(29):26886\u201326894. https:\/\/doi.org\/10.18632\/oncotarget.4723","journal-title":"Oncotarget"},{"issue":"3","key":"2167_CR12","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.yexmp.2015.09.004","volume":"99","author":"L Melchior","year":"2015","unstructured":"Melchior L, Grauslund M, Bellosillo B et al (2015) Multi-center evaluation of the novel fully-automated PCR-based Idylla BRAF mutation test on formalin-fixed paraffin-embedded tissue of malignant melanoma. Exp Mol Pathol 99(3):485\u2013491. https:\/\/doi.org\/10.1016\/j.yexmp.2015.09.004","journal-title":"Exp Mol Pathol"},{"issue":"3","key":"2167_CR13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jmoldx.2015.12.005","volume":"18","author":"AI Schiefer","year":"2016","unstructured":"Schiefer AI, Parlow L, Gabler L et al (2016) Multicenter evaluation of a novel automated rapid detection system of BRAF status in formalin-fixed, paraffin-embedded tissues. J Mol Diagn 18(3):370\u2013377. https:\/\/doi.org\/10.1016\/j.jmoldx.2015.12.005","journal-title":"J Mol Diagn"},{"issue":"3","key":"2167_CR14","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/jclinpath-2016-204025","volume":"70","author":"MK Yeo","year":"2017","unstructured":"Yeo MK, Jung MK, Lee SY et al (2017) The usefulness of a novel fully automated PCR-based Idylla test for detection of the BRAF V600E mutation in thyroid tissue: comparison with PNA-clamping PCR, real-time PCR and pyrosequencing. J Clin Pathol 70(3):260\u2013265. https:\/\/doi.org\/10.1136\/jclinpath-2016-204025","journal-title":"J Clin Pathol"},{"issue":"12","key":"2167_CR15","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.neo.2018.10.004","volume":"20","author":"H Taniguchi","year":"2018","unstructured":"Taniguchi H, Okamoto W, Muro K et al (2018) Clinical validation of newly developed multiplex kit using luminex xMAP technology for detecting simultaneous RAS and BRAF mutations in colorectal cancer: results of the RASKET-B study. Neoplasia 20(12):1219\u20131226. https:\/\/doi.org\/10.1016\/j.neo.2018.10.004","journal-title":"Neoplasia"},{"issue":"4","key":"2167_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ebiom.2015.02.007","volume":"2","author":"T Yoshino","year":"2015","unstructured":"Yoshino T, Muro K, Yamaguchi K et al (2015) Clinical validation of a multiplex kit for RAS mutations in colorectal cancer: results of the RASKET (RAS key testing) prospective multicenter study. EBioMedicine 2(4):317\u2013323. https:\/\/doi.org\/10.1016\/j.ebiom.2015.02.007","journal-title":"EBioMedicine"},{"issue":"4","key":"2167_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.23922\/jarc.2019-018","volume":"3","author":"Japenese society for cancer of the","year":"2019","unstructured":"Japenese society for cancer of the colon and rectum (2019) Japanese classification of colorectal, appendiceal, and anal carcinoma: the 3d English edition [secondary publication]. J Anus Rectum Colon 3(4):175\u2013195. https:\/\/doi.org\/10.23922\/jarc.2019-018","journal-title":"J Anus Rectum Colon"},{"issue":"4","key":"2167_CR18","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1136\/jclinpath-2017-204629","volume":"71","author":"L Johnston","year":"2018","unstructured":"Johnston L, Power M, Sloan P et al (2018) Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue. J Clin Pathol 71(4):336\u2013343. https:\/\/doi.org\/10.1136\/jclinpath-2017-204629","journal-title":"J Clin Pathol"},{"issue":"5","key":"2167_CR19","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/bjc.2011.19","volume":"104","author":"T Yokota","year":"2011","unstructured":"Yokota T, Ura T, Shibata N et al (2011) BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104(5):856\u2013862. https:\/\/doi.org\/10.1038\/bjc.2011.19","journal-title":"Br J Cancer"},{"key":"2167_CR20","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12885-015-1276-z","volume":"15","author":"A Kawazoe","year":"2015","unstructured":"Kawazoe A, Shitara K, Fukuoka S et al (2015) A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer 15:258. https:\/\/doi.org\/10.1186\/s12885-015-1276-z","journal-title":"BMC Cancer"},{"issue":"13","key":"2167_CR21","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.ejca.2015.05.017","volume":"51","author":"M Peeters","year":"2015","unstructured":"Peeters M, Kafatos G, Taylor A et al (2015) Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: a pooled analysis of randomised controlled trials. Eur J Cancer 51(13):1704\u20131713. https:\/\/doi.org\/10.1016\/j.ejca.2015.05.017","journal-title":"Eur J Cancer"},{"issue":"1","key":"2167_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1158\/1078-0432.CCR-16-0140","volume":"23","author":"D Barras","year":"2017","unstructured":"Barras D, Missiaglia E, Wirapati P et al (2017) BRAF V600E mutant colorectal cancer subtypes based on gene expression. Clin Cancer Res 23(1):104\u2013115. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0140","journal-title":"Clin Cancer Res"},{"issue":"6892","key":"2167_CR23","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949\u2013954. https:\/\/doi.org\/10.1038\/nature00766","journal-title":"Nature"},{"issue":"1","key":"2167_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ccell.2017.12.004","volume":"33","author":"R Yaeger","year":"2018","unstructured":"Yaeger R, Chatila WK, Lipsyc MD et al (2018) Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell 33(1):125\u2013136. https:\/\/doi.org\/10.1016\/j.ccell.2017.12.004","journal-title":"Cancer Cell"},{"issue":"1","key":"2167_CR25","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1016\/j.clcc.2017.10.006","volume":"17","author":"H Kayhanian","year":"2018","unstructured":"Kayhanian H, Goode E, Sclafani F et al (2018) Treatment and survival outcome of BRAF-mutated metastatic colorectal cancer: a retrospective matched case-control study. Clin Colorectal Cancer 17(1):e69\u2013e76. https:\/\/doi.org\/10.1016\/j.clcc.2017.10.006","journal-title":"Clin Colorectal Cancer"},{"key":"2167_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2021.104634","volume":"120","author":"T Haiduk","year":"2021","unstructured":"Haiduk T, Brockmann M, Tillmann RL et al (2021) Comparison of biocartis IDYLLA cartridge assay with Qiagen genereader NGS for detection of targetable mutations in EGFR, KRAS\/NRAS, and BRAF genes. Exp Mol Pathol 120:104634. https:\/\/doi.org\/10.1016\/j.yexmp.2021.104634","journal-title":"Exp Mol Pathol"},{"issue":"11","key":"2167_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0239819","volume":"15","author":"M Holm","year":"2020","unstructured":"Holm M, Andersson E, Osterlund E et al (2020) Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing. PLoS ONE 15(11):e0239819. https:\/\/doi.org\/10.1371\/journal.pone.0239819","journal-title":"PLoS ONE"},{"issue":"1","key":"2167_CR28","doi-asserted-by":"publisher","first-page":"8122","DOI":"10.1038\/s41598-020-64822-7","volume":"10","author":"DCL Vessies","year":"2020","unstructured":"Vessies DCL, Greuter MJE, van Rooijen KL et al (2020) Performance of four platforms for KRAS mutation detection in plasma cell-free DNA: ddPCR, Idylla, COBAS z480 and beaming. Sci Rep 10(1):8122. https:\/\/doi.org\/10.1038\/s41598-020-64822-7","journal-title":"Sci Rep"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-022-02167-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-022-02167-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-022-02167-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T04:06:01Z","timestamp":1655697961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-022-02167-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,26]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["2167"],"URL":"https:\/\/doi.org\/10.1007\/s10147-022-02167-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,26]]},"assertion":[{"value":"1 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takao Satou, Hidekazu Yamamoto, Kazuto Nishio, and Junichiro Kawamura received funding from Nichirei Biosciences Inc. (Tokyo, Japan) for this study. No other financial support was provided.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}